We serve Chemical Name:Osteocalcin (45-49) (human) CAS:85679-70-5 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
Chemical Name:Osteocalcin (45-49) (human)
CAS.NO:85679-70-5
Synonyms:OSTEOCALCIN,Fragment 45-49;Phe-Tyr-Gly-Pro-Val;Osteocalcin Fragment 45-49 human;FYGPV
Molecular Formula:C30H39N5O7
Molecular Weight:581.66000
HS Code:
Physical and Chemical Properties:
Melting point:N/A
Boiling point:N/A
Density:N/A
Index of Refraction:
PSA:191.16000
Exact Mass:581.28500
LogP:2.13300
Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:NONH for all modes of transpor
Packing Group:
Contact us for information like OSTEOCALCIN,Fragment 45-49 chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,FYGPV physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,FYGPV Use and application,OSTEOCALCIN,Fragment 45-49 technical grade,usp/ep/jp grade.
Related News: The expansion will include six 1,000L small molecule reactors, four 1,500L vessels, and isolation equipment providing mid-scale capacity to bridge between early-phase and late-phase production. acetic acid,2-[(dodecyl-methyl-octylsilyl)oxy-ethyl-methylsilyl]ethanol manufacturers Flexibility in a CDMO is the key to ensure speed of tech-transfer which is a true litmus test for CDMOs which can help a company chose between competing analytical strategies, manufacturing technology and knowledge for improving productivity. 2-Allyl-5-chlorcarbonyl-1,2,5-thiadiazolidin-1,1-dioxid suppliers Grégoire Boutonnet, Chief Operating Officer of NOVA, said: “I am thrilled to be joining the NOVA team at this exciting period of growth as we launch the Jinkō platform towards wider adoption in the clinical trial development space. 3,9-bis(N,N-dimethylamino)-2,4,8,10-tetraoxa-3,9-diphosphaspiro[5.5]undecane-3,9-dioxide vendor & factory Grégoire Boutonnet, Chief Operating Officer of NOVA, said: “I am thrilled to be joining the NOVA team at this exciting period of growth as we launch the Jinkō platform towards wider adoption in the clinical trial development space. ,This also includes experience for drug delivery systems, efficient teams, facilities, and production capabilities.
